PMID- 9231787
OWN - NLM
STAT- MEDLINE
DCOM- 19970815
LR  - 20071114
IS  - 0013-7227 (Print)
IS  - 0013-7227 (Linking)
VI  - 138
IP  - 8
DP  - 1997 Aug
TI  - Direct administration of insulin-like growth factor to fetal rhesus monkeys 
      (Macaca mulatta).
PG  - 3349-58
AB  - A potential treatment for the amelioration of fetal growth failure is 
      insulin-like growth factor-I (IGF-I). To address concerns of safety and efficacy, 
      IGF-I (80 microg/kg; GroPep Pty.) was administered i.p. to healthy rhesus monkey 
      fetuses via ultrasound guidance every other day between gestational days (GD) 
      110-120 and 130-140 (third trimester; term = approximately GD 165 +/- 10; n = 6). 
      Pregnancies were monitored sonographically, and fetal/maternal blood samples were 
      collected for complete blood counts, immunophenotyping, and biochemical analyses. 
      Blood samples, external measures of the fetus and newborn, and tissue and organ 
      weights were collected at fetal necropsy (GD 150; n = 2) or at term delivery of 
      neonates (GD 160; n = 4). The results of these investigations have shown no 
      evidence of hypoglycemia in the fetus or dam during the course of treatment. 
      Circulating concentrations of fetal, but not maternal, IGF-I increased with 
      treatment (approximately 80 to approximately 1015 ng/ml), and there was no 
      evidence of a change in serum IGF-II or an increase in IGF binding protein-3 
      compared with historical control values. Fetal lymphocytes and select red cell 
      parameters increased, and a significant elevation in circulating B cells and 
      CD4/CD8 ratios in fetal lymph nodes was shown. Although no changes were detected 
      in body weights, increases in thymic, splenic, and kidney weights and small 
      intestine lengths occurred. Thus, administration of IGF-I to the fetal monkey is 
      safe and results in 1) transient increases in circulating IGF-I, 2) a significant 
      effect on fetal hematopoietic and lymphoid tissues, and 3) an increase in select 
      fetal organ weights and measures. These data suggest that IGF-I may represent a 
      potential candidate for therapeutic treatment of growth-compromised human fetuses 
      in utero.
FAU - Tarantal, A F
AU  - Tarantal AF
AD  - California Regional Primate Research Center and the Department of Pediatrics, 
      University of California, Davis 95616, USA. aftarantal@ucdavis.edu
FAU - Hunter, M K
AU  - Hunter MK
FAU - Gargosky, S E
AU  - Gargosky SE
LA  - eng
GR  - DK-49317/DK/NIDDK NIH HHS/United States
GR  - RR-00169/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
SB  - IM
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Blotting, Western
MH  - CD4-CD8 Ratio
MH  - Disease Models, Animal
MH  - Embryonic and Fetal Development/*drug effects/physiology
MH  - Female
MH  - Fetal Growth Retardation/drug therapy
MH  - Fetus/*drug effects/metabolism/physiology
MH  - Gestational Age
MH  - Immunophenotyping
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor I/metabolism/*pharmacology/therapeutic use
MH  - Insulin-Like Growth Factor II/analysis/metabolism
MH  - Kidney/anatomy & histology/embryology
MH  - Macaca mulatta/*embryology/metabolism/physiology
MH  - Organ Size
MH  - Pregnancy
MH  - Spleen/anatomy & histology/embryology
MH  - Thymus Gland/anatomy & histology/embryology
MH  - Ultrasonography, Prenatal
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1210/endo.138.8.5300 [doi]
PST - ppublish
SO  - Endocrinology. 1997 Aug;138(8):3349-58. doi: 10.1210/endo.138.8.5300.